Back to results
US 2024/0252633 A1Published application
Methods of treating cancer with cd-40 agonists
AssigneeApexigen America, Inc.
InventorsLacey Padron, Theresa Lavallee, Pier Federico Gherardini, Deena Maurer
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of identifying a sub-population of cancer patients amendable for a combination therapy with a CD40 agonist and one or more chemotherapy drugs and treating the sub-population of cancer patients with the combination therapy.
Claims24
1-42. (canceled)
A method of treating a cancer in a human subject in need thereof, comprising:
- (a) determining levels (cell counts) of at least one circulating peripheral blood mononuclear cell (PBMC) type selected from a group consisting of:
- HLA-DR+CCR7+B cells, cross-presenting dendritic cells (DCs), CD1C+CD141+cross-presenting DCs, PD-1+ T cells, TCF-1+ T cells, Tbet+ T cells, and T helper cells, in a biological sample from the subject;
- and
- (b) administering a CD40 agonist in combination with a chemotherapeutic agent to the subject if the levels (cell counts) of at least one circulating PMBCs type select from a group consisting of:
- HLA-DR+CCR7+B cells, cross-presenting DCs, CD1C+CD141+cross-presenting DCs, PD-1+ T cells, TCF-1+ T cells, Tbet+ T cells, and T helper cells, are increased relative to a control or reference.
2 more elements
A method of treating a cancer in a human subject in need thereof, comprising:
- (a) determining levels (cell counts) of circulating 2B4+CD4 T cells in a biological sample from the subject;
- and
- (b) administering a CD40 agonist in combination with a chemotherapeutic agent to the subject if the levels (cell counts) of circulating 2B4+CD4 T cells are decreased relative to a control or reference.
A method of treating a cancer in a human subject in need thereof, comprising:
- (a) determining a gene signature in a biological sample from the subject, where in the gene signature is the MYC gene signature or the E2F gene signature, and calculating a signature score;
- and
- (b) administering a CD40 agonist in combination with a chemotherapeutic agent to the subject if the gene signature score is decreased relative to a control or reference.
Dependencies are inferred from the claim text.